Last edition
News about Clinical Trials
Accession Therapeutics Doses First Patient in Phase 1 Trial of TROCEPT-01
Accession Therapeutics has dosed the first patient in its Phase 1 trial of TROCEPT-01 (ATTR-01), a first-in-class tumour-activated viral immunotherapy. Designed for systemic delivery, the therapy aims to selectively generate a checkpoint inhibitor within tumours, offering a targeted approach to cancer treatment.
Clinical Trials | 18/11/2025 | By Dineshwori
Vanda's Tradipitant Shows Strong Efficacy in Preventing Wegovy-Induced Nausea and Vomiting
Vanda Pharmaceuticals has announced positive topline results from its randomised controlled study evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for preventing nausea and vomiting associated with GLP-1 receptor agonist Wegovy in overweight and obese adults.
Clinical Trials | 18/11/2025 | By Dineshwori
Moleculin Launches Grant-Funded Study of Annamycin for Pancreatic Cancer at UNC-Chapel Hill
Moleculin has initiated a grant-funded preclinical programme at the University of North Carolina at Chapel Hill to evaluate Annamycin in pancreatic cancer, including its use alongside novel therapeutic agents and modalities. Early studies suggest Annamycin may effectively target key drivers of the disease.
Clinical Trials | 15/11/2025 | By Dineshwori
In the pivotal FENtrepid trial, Roche’s BTK inhibitor fenebrutinib demonstrated a meaningful reduction in disability progression in Primary Progressive Multiple Sclerosis (PPMS), performing at least on par with OCREVUS—the current standard and only approved treatment for PPMS.
Clinical Trials | 15/11/2025 | By Dineshwori
Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek 2025
Sun Pharma presented new clinical data on its investigational GLP-1 agonist, Utreglutide, at ObesityWeek 2025, highlighting meaningful reductions in body weight, waist circumference, and lipid parameters across two studies, with the therapy showing a favourable and class-consistent safety profile.
Clinical Trials | 14/11/2025 | By Dineshwori
Novartis Reports Promising Results for New Anti-Malaria Drug to Tackle Growing Resistance
Novartis’ Phase III trial of KLU156 (GanLum) met its primary endpoint, showing a 97.4 percent PCR-corrected cure rate comparable to Coartem. If approved, GanLum would mark the first major malaria treatment breakthrough in over two decades, targeting drug-resistant parasites.
Clinical Trials | 13/11/2025 | By Dineshwori
Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.
Clinical Trials | 12/11/2025 | By Dineshwori | 104
Sun Pharmaceutical’s partner Philogen, a Swiss-Italian biotechnology company, has provided an update on the Phase III FIBROSARC trial evaluating Fibromun (L19TNF) in combination with doxorubicin versus doxorubicin alone as first-line treatment for patients with advanced or metastatic Soft Tissue Sarcoma (STS).
Clinical Trials | 12/11/2025 | By Dineshwori
OrtoWell Hydraulic Distractor System Proven Safe and Effective in First Multi-Centre Clinical Study
OrtoWay-US Inc, the US-German MedTech innovator focused on spinal surgery tools for orthopedic vertebral separation, has announced the publication of the first prospective, multi-center clinical study evaluating its OrtoWell Distractor System – the world's first hydraulically powered vertebral distractor.
Clinical Trials | 11/11/2025 | By Dineshwori
Phase 3 results show Dupixent significantly improved nasal symptoms and sinus health in patients aged six and above with allergic fungal rhinosinusitis, supporting its FDA priority review.
Clinical Trials | 10/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy